Monday, 9 August 2010
AstraZeneca announced today that, as of 9 August, it had reached agreements in principle on monetary terms with attorneys representing approximately 17,500 SEROQUEL product liability claimants in the United States for approximately $198 million. The agreements in principle are subject to agreement on non-monetary terms.
As of 30 June 2010, no provision had been made in respect of any settlements. Any provision would be disregarded in calculating Core earnings and, as such, the Company’s Core earnings per share guidance for 2010 remains unchanged at $6.35-$6.65.
The specific terms of the agreements, which are the result of court-ordered mediation, are confidential. AstraZeneca continues to participate in the mediation process covering claims in both federal and state jurisdictions.
As of 29 June, approximately 2,900 additional cases have been dismissed by order or agreement and approximately 1,825 of those cases have been dismissed with prejudice. The only jury trial to date resulted in a defence verdict in favour of AstraZeneca.
NOTES TO EDITORS:
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business
with a primary focus on the discovery, development and commercialisation
of prescription medicines. As a leader in gastrointestinal,
cardiovascular, neuroscience, respiratory and inflammation, oncology and
infectious disease medicines, AstraZeneca generated global revenues of
US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com.
CONTACTS:
Media Enquiries:
Neil McCrae +44 207 304 5045 (24 hours)
Chris Sampson +44 20 7304 5130 (24 hours)
Sarah Lindgreen +44 20 7304 5033 (24 hours)
Abigail Baron +44 20 7304 5034 (24 hours)
Investor Enquiries UK:
Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032
Karl Hard +44 207 304 5322 mob: +44 7789 654364
Investor Enquiries US:
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043